External radiotherapy and anaemia treatment: state of the art.

Détails

Ressource 1Télécharger: 15662573.pdf (284.02 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_8BEEB0A26553
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
External radiotherapy and anaemia treatment: state of the art.
Périodique
Swiss medical weekly
Auteur(s)
Ozsahin M., Azria D., Beer K., Mirimanoff R.O., Zouhair A.
ISSN
1424-7860 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
08/01/2005
Peer-reviewed
Oui
Volume
135
Numéro
1-2
Pages
4-10
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Anaemia is considered a common problem in many cancers secondary to the disease itself or related to chemo- and/or radiotherapy. Several clinical trials have advocated the prognostic value of anaemia and hypoxia in the outcome of many cancers. Erythropoietin is recognised as an effective treatment for anaemia, which also improves the quality of life in patients with malignant disease. External radiotherapy plays an important role in the treatment of loco-regional cancer but its efficacy can be compromised by many factors. Tumor hypoxia is considered by many authors as an important factor contributing to radioresistance. We report in this article the radiobiological rationale in favour of combining radiotherapy and erythropoietin, and review relevant clinical papers published in this field.

Mots-clé
Anemia/drug therapy, Anemia/etiology, Clinical Trials as Topic, Combined Modality Therapy, Epoetin Alfa, Erythropoietin/therapeutic use, Hematinics/therapeutic use, Humans, Neoplasms/complications, Neoplasms/radiotherapy, Recombinant Proteins, Treatment Outcome
Pubmed
Web of science
Création de la notice
24/01/2008 18:20
Dernière modification de la notice
11/06/2018 12:25
Données d'usage